Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)
An urgent need exists for antibiotics to treat infections caused by carbapenem-resistant Acinetobacter baumannii–calcoaceticus complex (ABC).The article presents the findings of a phase 3 clinical trial comparing the efficacy and safety of the antibiotic combination sulbactam-durlobactam to colistin for the treatment of serious infections caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (ABC).
Source: Lancet Infectious Diseases